AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study as part of the I-SPY 2 trial, sponsored and operated by Quantum Leap ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of a new study in the Journal of Clinical Oncology Precision Oncology (JCO PO), ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
AMPLIFY-201, a phase I trial evaluating treatment response to the ELI-002 vaccine, is the first study to read out using ctDNA to enroll and monitor patients with solid tumors PANDA study shows ctDNA ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
Natera Inc. (NASDAQ: NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer ...
Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings This recently published, real-world, multi-center, retrospective study analyzed 233 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback